Dementia affects millions of people around the world, yet getting an accurate diagnosis remains one of the biggest challenges in brain health.
Many forms of dementia share similar symptoms, including memory loss, confusion, difficulty thinking, and changes in behavior. As a result, doctors often struggle to determine exactly which disease is causing a person’s symptoms.
The challenge becomes even greater because several brain diseases can occur at the same time. A patient may have Alzheimer’s disease alongside Parkinson’s disease or another neurodegenerative condition. However, current diagnostic tools are often designed to identify only one disease at a time, making it difficult to capture the full picture.
Researchers at Washington University School of Medicine in St. Louis have now developed a promising new approach. Using artificial intelligence and a simple blood test, they created a tool that can distinguish between several major causes of dementia with impressive accuracy. The findings were published in the journal Alzheimer’s & Dementia.
The new system focuses on four common neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and dementia with Lewy bodies. It can also distinguish these conditions from normal age-related cognitive changes.
One of the most important features of the tool is its ability to identify when more than one disease process is occurring in the same person. This is a common situation among older adults but is often missed during routine medical evaluations.
According to senior researcher Dr. Carlos Cruchaga, the goal was to move beyond simple yes-or-no diagnoses. Instead of telling doctors that a patient either has or does not have Alzheimer’s disease, the new system provides information about multiple disease processes that may be occurring simultaneously.
To create the test, researchers selected 15 proteins that can be measured in the blood. These proteins act as biological signals that reflect what is happening inside the brain. Some are linked to Alzheimer’s disease, while others are associated with nerve damage, inflammation, or the loss of connections between brain cells.
The team used blood samples from more than 3,200 individuals. These participants included people diagnosed with Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies, and healthy individuals without cognitive impairment.
Artificial intelligence was then trained to recognize patterns within the protein data. By analyzing these patterns, the system learned how different diseases affect blood protein levels.
The researchers later tested the AI system on a separate group of 225 people. These individuals had undergone cognitive assessments during their lives, and their brains were examined after death. This allowed researchers to compare the AI’s predictions with the actual disease changes found in brain tissue.
The results were highly encouraging. The system achieved an overall diagnostic accuracy of 92.3 percent when identifying patients with a single neurodegenerative disease. Even more importantly, it showed an ability to detect mixed disease patterns that standard clinical assessments often miss.
The tool also performed well in patients with mild cognitive impairment or unclear neurological diagnoses. In these situations, the AI’s predictions closely matched the amount of disease-related brain changes later confirmed during autopsy.
For example, some patients who had been diagnosed with Parkinson’s disease during life showed Alzheimer’s-related changes in their brains after death. The AI system was often able to detect these hidden Alzheimer’s-like patterns while the patients were still alive.
This ability could be extremely valuable because treatments may differ depending on the diseases involved. A more complete diagnosis could help doctors make better decisions about medications, monitoring, and future care planning.
The technology may also accelerate research. Clinical trials often fail because participants have different underlying diseases despite having similar symptoms. A blood test that accurately identifies disease types could help researchers enroll the right patients in the right studies.
The researchers emphasize that the test is not yet ready for everyday clinical use. More studies involving larger and more diverse populations are needed. Scientists also need to follow patients over time to determine how well the test predicts future disease progression.
Nevertheless, the findings represent an important step toward precision medicine for dementia. Current diagnostic methods often require expensive brain scans, spinal fluid tests, or lengthy evaluations. A simple blood test could make advanced diagnosis faster, cheaper, and more widely available.
Study analysis: One of the greatest strengths of this study is the large number of participants and the use of autopsy-confirmed diagnoses, which provides a highly reliable way to evaluate accuracy. The ability to identify multiple overlapping diseases is particularly important because mixed dementia is common in older adults.
Although further validation is necessary before clinical adoption, the 92.3% accuracy rate and strong correlation with actual brain pathology suggest that this technology has significant potential to improve dementia diagnosis and personalize future treatments.
If you care about dementia, please read studies about the power of healthy fats for brain health, and wild blueberries can benefit your heart and brain..
For more health information, please see recent studies about how eating nuts can affect your cognitive ability ,and brain foods nourish your mind to outsmart dementia.
Source: Washington University School of Medicine in St. Louis.
